POLO 样激酶 1 抑制在 KRAS 突变转移性结直肠癌中的作用。
Polo-like Kinase 1 Inhibition in KRAS-Mutated Metastatic Colorectal Cancer.
机构信息
Department of Life Sciences, Anglia Ruskin University, Cambridge, United Kingdom.
Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
出版信息
Clin Cancer Res. 2024 May 15;30(10):2005-2007. doi: 10.1158/1078-0432.CCR-24-0251.
Abstract
Inhibition of Polo-like kinase 1 (Plk1) is a promising new target and therapeutic strategy in metastatic colorectal cancer, especially those with KRAS mutations. New data support further development of onvansertib, and highlights the role of circulating tumor DNA in phase I clinical trials. See related article by Ahn et al., p. 2039.
摘要
抑制 Polo 样激酶 1（Plk1）是转移性结直肠癌（尤其是 KRAS 突变型）的一个很有前途的新靶点和治疗策略。新数据支持进一步开发 onvansertib，并强调了循环肿瘤 DNA 在 I 期临床试验中的作用。参见 Ahn 等人的相关文章，第 2039 页。
Zotero 插件